Clinical Trial Update: A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II) [Phase 3]

View source ↗

Summary

Phase 3 trial AbESTT-II evaluating Abciximab for acute ischemic stroke was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Abciximab (abciximab)

Snippet

Sponsor: Centocor, Inc. | Conditions: Cerebrovascular Accident, Brain Ischemia | Phase 3 | Status: TERMINATED